Get Premium to unlock powerful stock data
Relay Therapeutics Inc logo

Relay Therapeutics Inc

$ 16.65 -0.97 (-5.51%) 04:00 PM EST
P/E:
At Loss
P/B:
2.24
Market Cap:
$ 1.81B
Enterprise V:
$ 1.04B
Volume:
548.67K
Avg Vol (2M):
781.25K
Volume:
548.67K
Market Cap $:
1.81B
PE Ratio:
At Loss
Avg Vol (2-Month):
781.25K
Enterprise Value $:
1.04B
PB Ratio:
2.24
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Relay Therapeutics Inc
NAICS : 541714 SIC : 2834
399 Binney Street, 2nd Floor, Cambridge, MA, USA, 02139
Description
Relay Therapeutics Inc is a clinical-stage, precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is advancing its pipeline of medicines to address targets in precision oncology, including its lead product candidates, RLY-4008 and RLY-1971, as well as its PI3Ka mutant selective program, known as the RLY-PI3K1047 program. Its initiated a Phase 1 clinical trial for RLY-1971 in patients with advanced solid tumors in the first quarter of 2020 and a first-in-human clinical trial of RLY-4008 enriched for patients with advanced solid tumors having oncogenic FGFR2 alterations in the third quarter of 2020.
Name Current Vs Industry Vs History
Cash-To-Debt 39.96
Equity-to-Asset 0.89
Debt-to-Equity 0.03
Debt-to-EBITDA -0.09
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 9.2
Distress
Grey
Safe
Beneish M-Score -9.77
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -47.6
3-Year EPS without NRI Growth Rate -72.4
3-Year FCF Growth Rate -5.4

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 42.56
9-Day RSI 35.11
14-Day RSI 35.2
6-1 Month Momentum % -11.74
12-1 Month Momentum % -7.28

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 21.97
Quick Ratio 21.97
Cash Ratio 21.54
Days Sales Outstanding 64.16

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -18.3

Profitability Rank

Name Current Vs Industry Vs History
Operating Margin % -10092.87
Net Margin % -15373.96
ROE % -52.39
ROA % -46.62
ROIC % -670.39
ROC (Joel Greenblatt) % -897.82
ROCE % -31.65

Financials (Next Earnings Date:2022-08-12 Est.)

RLAY's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:RLAY

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Performance
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 2.496
EPS (TTM) ($) -3.95
Beta 0
Volatility % 50.6
14-Day RSI 35.2
14-Day ATR ($) 2.157533
20-Day SMA ($) 20.489
12-1 Month Momentum % -7.28
52-Week Range ($) 14.37 - 38.605
Shares Outstanding (Mil) 108.66

Piotroski F-Score Details

Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Relay Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More